Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Cited by (1,009)

Items 501–600 of 1,009

1. Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways
   Bai, Xue, Fisher, David E., Flaherty, Keith T. · 2019 · Nature Reviews Clinical Oncology
2. Tumour Microenvironment (TME) Characterization Identified Prognosis and Immunotherapy Response in Muscle-Invasive Bladder Cancer (MIBC)
   Rui Cao, Lushun Yuan, Bo Ma, Gang Wang, Wei Qiu, Ye Tian · 2019 · Cancer Immunology Immunotherapy
3. Multi-scale integrative analyses identify THBS2+ cancer-associated fibroblasts as a key orchestrator promoting aggressiveness in early-stage lung adenocarcinoma
   Haitang Yang, Beibei Sun, Liwen Fan, Wenyan Ma, Ke Xu, Sean R. R. Hall, Zhexin Wang, Ralph Alexander Schmid, Ren‐Wang Peng, Thomas M. Marti et al. · 2022 · Theranostics
4. RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas
   Manfred Kunz, Henry Loeffler‐Wirth, Michael Dannemann, Edith Willscher, Gero Doose, Janet F. Kelso, Tina Kottek, Birgit Nickel, Lydia Hopp, Jenny Landsberg et al. · 2018 · Oncogene
5. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches
   Dongkui Song, Thomas B. Powles, Lei Shi, Lirong Zhang, Molly A. Ingersoll, Yong‐Jie Lu · 2019 · The Journal of Pathology
6. Prognostic value of B cells in cutaneous melanoma
   Sara R. Selitsky, Lisle E. Mose, Christof C. Smith, Shengjie Chai, Katherine A. Hoadley, Dirk P. Dittmer, Stergios J. Moschos, Joel S. Parker, Benjamin Garrett Vincent · 2019 · Genome Medicine
7. Photothermal therapy mediated by phase-transformation nanoparticles facilitates delivery of anti-PD1 antibody and synergizes with antitumor immunotherapy for melanoma
   Ni Zhang, Jiao Song, Yi Liu, Mingzhu Liu, Liang Zhang, Danli Sheng, Liming Deng, Hengjing Yi, Meng Wu, Yuanyi Zheng et al. · 2019 · Journal of Controlled Release
8. Microneedles loaded with anti-PD-1–cisplatin nanoparticles for synergistic cancer immuno-chemotherapy
   Xinmiao Lan, Wang‐Yong Zhu, Xinshuo Huang, Yingjie Yu, Haihua Xiao, Lijian Jin, Jingya Jane Pu, Xi Xie, Juncong She, Vivian Wai Yan Lui et al. · 2020 · Nanoscale
9. An algorithm to quantify intratumor heterogeneity based on alterations of gene expression profiles
   Mengyuan Li, Zhilan Zhang, Lin Li, Xiaosheng Wang · 2020 · Communications Biology
10. The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials
    Marco Donia, Marie Louise Kimper-Karl, Katrine Lundby Høyer, Lars Bastholt, Henrik Schmidt, Inge Marie Svane · 2017 · European Journal of Cancer
11. Epigenetic modifiers as new immunomodulatory therapies in solid tumours
    Sandrine Aspeslagh, Daphné Morel, Jean‐Charles Soria, Sophie C. Postel-Vinay · 2018 · Annals of Oncology
12. Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
    Laura Boyero, Amparo Sánchez-Gastaldo, Miriam D. Alonso, José Francisco Noguera-Uclés, Sonia Molina‐Pinelo, Reyes Bernabé · 2020 · Cancers
13. Tumor-secreted FGF21 acts as an immune suppressor by rewiring cholesterol metabolism of CD8+T cells
    Cegui Hu, Wen Qiao, Xiang Olivia Li, Zhikun Ning, Jiang Liu, Sumiya Dalangood, Hanjun Li, Xiang Yu, Zhen Zong, Zhenke Wen et al. · 2024 · Cell Metabolism
14. Global Cancer Transcriptome Quantifies Repeat Element Polarization between Immunotherapy Responsive and T Cell Suppressive Classes
    Alexander Solovyov, Nicolas Vabret, Kshitij Satnamdas Arora, Alexandra Snyder, Samuel Aaron Funt, Dean F. Bajorin, Jonathan E. Rosenberg, Nina Bhardwaj, David Tsai Ting, Benjamin D. Greenbaum · 2018 · Cell Reports
15. Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers
    Masaru Katoh · 2019 · Clinical Science
16. Immune checkpoint inhibitors for hepatocellular carcinoma
    Imane El Dika, Danny N. Khalil, Ghassan K. Abou‐Alfa · 2019 · Cancer
17. Targeting DNA repair in cancer: current state and novel approaches
    Apostolos Klinakis, Dimitris Karagiannis, Theodoros N Rampias · 2019 · Cellular and Molecular Life Sciences
18. Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models
    Qiaohong Wang, Jingze Gao, Wen J. Di, Xia Wu · 2020 · Cancer Immunology Immunotherapy
19. Prognostic significance of immune landscape in tumour microenvironment of endometrial cancer
    Bilan Li, Xiaoping Wan · 2020 · Journal of Cellular and Molecular Medicine
20. Escape from nonsense-mediated decay associates with anti-tumor immunogenicity
    Kevin Litchfield, James L. Reading, Emilia L. Lim, Hang Xu, Po Liu, Maise Al Bakir, Yien Ning Sophia Wong, Andrew Rowan, Samuel Aaron Funt, Taha Merghoub et al. · 2020 · Nature Communications
21. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
    Robert I. Haddad, Tanguy Y. Seiwert, Laura Q.M. Chow, Shilpa Gupta, Jared Weiss, Iris Gluck, Joseph P. Eder, Barbara Ann Burtness, Makoto Tahara, Bhumsuk Keam et al. · 2022 · Journal for ImmunoTherapy of Cancer
22. Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics
    Jing Zhang, Zhimin Hu, Calista A. Horta, Jing Yang · 2022 · Seminars in Cancer Biology
23. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial
    Byoung Chul Cho, Jong Seok Lee, Yi-Long Lung Cancer Wu, İrfan Çiçin, Manuel Cobo, Myung‐Ju Ahn, Kristof Cuppens, Rémi Veillon, Ernest Nadal, Josiane Mourão Dias et al. · 2023 · Journal of Thoracic Oncology
24. CD8+ T cell-based cancer immunotherapy
    Yanxia Chen, Dingning Yu, Hui Qian, Ying–Hong Shi, Zhimin Tao · 2024 · Journal of Translational Medicine
25. The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression
    Huang, Lu, Malu, Shruti, McKenzie, Jodi A., Andrews, Miles C., Talukder, Amjad H., Tieu, Trang, Karpinets, Tatiana, Haymaker, Cara, Forget, Marie-Andrée, Williams, Leila J. et al. · 2018 · Clinical Cancer Research
26. Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application
    Nancy Tray, Jeffrey S. Weber, Sylvia Adams · 2018 · Cancer Immunology Research
27. Immune‐related long noncoding RNA signature for predicting survival and immune checkpoint blockade in hepatocellular carcinoma
    Yaqiong Zhang, Liming Zhang, Youwen Xu, Xiaoyu Wu, Yong Zhou, Jinggang Mo · 2020 · Journal of Cellular Physiology
28. Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response
    Jessica P Roelands, Wouter Hendrickx, Gabriele M. Zoppoli, Raghvendra Mall, Mohamad Saad, Kyle D. Halliwill, Giuseppe Curigliano, Darawan Rinchai, Julie V. Decock, Lucia Gemma Delogu et al. · 2020 · Journal for ImmunoTherapy of Cancer
29. Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion
    Nicholas C. DeVito, Michael P. Plebanek, Bala Theivanthiran, Brent Allen Hanks · 2019 · Frontiers in Immunology
30. Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation
    Yixuan Zhou, Ingmar Niels Bastian, Mark D. Long, Michelle T. Dow, Weihua Li, Tao Liu, Rachael Katie Ngu, Laura Antonucci, Jian Yu Huang, Qui T. Phung et al. · 2021 · Proceedings of the National Academy of Sciences
31. Cancer-associated MSC drive tumor immune exclusion and resistance to immunotherapy, which can be overcome by Hedgehog inhibition
    Sandra Cascio, Chelsea Chandler, Linan Zhang, Sarah Sinno, Bingsi Gao, Sayali Onkar, Tullia Carmela Bruno, Dario A.A. Vignali, Haider Mahdi, Hatice U. Osmanbeyoglu et al. · 2021 · Science Advances
32. Integrated Multi-Omics Landscape of Liver Metastases
    Shuai Yang, Ling Qian, Zhixuan Li, Ye Li, Jian Bai, Bo Jian Zheng, Kun Chen, Xinyao Qiu, Guoxiang Cai, Shan Wang et al. · 2022 · Gastroenterology
33. Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma
    Yu, Jiayi, Yan, Junya, Guo, Qian, Chi, Zhihong, Tang, Bixia, Zheng, Bin, Yu, Jinyu, Yin, Ting, Cheng, Zhiyuan, Wu, Xiaowen et al. · 2019 · Clinical Cancer Research
34. Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors
    Shannon M. Steinberg, Tamer Basel Shabaneh, Peisheng Zhang, Viktor Martyanov, Zhenghui Li, Brian T. Malik, Tamara A. Wood, Andrea Boni, Aleksey K. Molodtsov, Christina Vadala Angeles et al. · 2017 · Cancer Research
35. The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors
    Ravindra Pramod Deshpande, Sambad Sharma, Kounosuke Watabe · 2020 · Cancers
36. ZEB1 transcription factor promotes immune escape in melanoma
    Maud Plaschka, Valentin Benboubker, Maxime Grimont, Justine Berthet, Laurie Tonon, Jonathan Lopez, Myrtille Le Bouar, B. Balme, Garance Tondeur, Arnaud de la Fouchardière et al. · 2022 · Journal for ImmunoTherapy of Cancer
37. Immunotherapy for colorectal cancer: where are we heading?
    Debora Basile, Silvio Ken Garattini, Marta Bonotto, Elena Ongaro, Mariaelena Casagrande, Monica Cattaneo, Valentina Fanotto, Elisa De Carlo, Fotios Loupakis, Federica Urbano et al. · 2017 · Expert Opinion on Biological Therapy
38. Dietary glutamine supplementation suppresses epigenetically-activated oncogenic pathways to inhibit melanoma tumour growth
    Mari B. Ishak Gabra, Ying Yang, Haiqing Li, Parijat Senapati, Eric Allan Hanse, Xazmin H. Lowman, Thai Q. Tran, Lishi Zhang, Linda T. Doan, Xiangdong Xu et al. · 2020 · Nature Communications
39. Hypoxia-driven intratumor heterogeneity and immune evasion
    Stéphane Terry, Agnete S. T. Engelsen, Stéphanie Buart, Walid El‐Sayed, Goutham Hassan Venkatesh, Salem Chouaı̈b · 2020 · Cancer Letters
40. Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models
    Zhiqiang Guo, Yan Li, Dandan Zhang, Jiaying Ma · 2017 · Oncotarget
41. Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors
    Alexandre Perrier, Audrey Didelot, Pierre Laurent‐Puig, Hélène Blons, Simon Garinet · 2020 · Biomolecules
42. Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma
    Jani Huuhtanen, Henna H.E. Kasanen, Katriina Johanna Peltola, Tapio Lönnberg, Virpi Glumoff, Oscar E. Brück, Olli Dufva, Karita Peltonen, Johanna Vikkula, Emmi Jokinen et al. · 2023 · Journal of Clinical Investigation
43. Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses
    Lo, Jennifer A., Kawakubo, Masayoshi, Juneja, Vikram R., Su, Mack Y., Erlich, Tal H., LaFleur, Martin W., Kemeny, Lajos V., Rashid, Mamunur, Malehmir, Mohsen, Rabi, S. Alireza et al. · 2021 · Science Translational Medicine
44. TAM family kinases as therapeutic targets at the interface of cancer and immunity
    Deborah DeRyckere, Justus M. Huelse, Henry Shelton Earp, Douglas K. Graham · 2023 · Nature Reviews Clinical Oncology
45. Sequencing Treatment in BRAF V600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition
    Douglas Buckner Johnson, Eirini Pectasides, Emily Feld, Fei Ye, Shilin Zhao, Romany Anne Nilanthi Johnpulle, Ryan M. Merritt, David F. McDermott, Igor J. Puzanov, Donald P. Lawrence et al. · 2016 · Journal of Immunotherapy
46. Glycocalyx-Mimicking Nanoparticles Improve Anti-PD-L1 Cancer Immunotherapy through Reversion of Tumor-Associated Macrophages
    Yufei Zhang, Libin Wu, Zhen Li, Weiyi Zhang, Feifei Luo, Yiwei Chu, Guosong Chen · 2018 · Biomacromolecules
47. Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer
    Donghai Xiong, Yian Wang, Arun K. Singavi, Alexander Craig Mackinnon, Ben George, Ming You · 2018 · iScience
48. Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy
    Janelle C. Waite, Bei Wang, Lauric Haber, Aynur Hermann, Erica Ullman, Xuan Ye, Drew Dudgeon, Rabih M. Slim, Dharani K. Ajithdoss, Stephen Godin et al. · 2020 · Science Translational Medicine
49. EMT-Inducing Transcription Factors, Drivers of Melanoma Phenotype Switching, and Resistance to Treatment
    Yaqi Tang, Simon Durand, Stéphane Dalle, Julie Caramel · 2020 · Cancers
50. STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity
    Falahat, Rana, Perez-Villarroel, Patricio, Mailloux, Adam W., Zhu, Genyuan, Pilon-Thomas, Shari, Barber, Glen N., Mulé, James J. · 2019 · Cancer Immunology Research
51. DNA repair defects and implications for immunotherapy
    Katherine M. Bever, Dung Thi Le · 2018 · Journal of Clinical Investigation
52. The Cancer Immunotherapy Biomarker Testing Landscape
    Eric E. Walk, Sophia Louise Yohe, Amy Beckman, Andrew E. Schade, Mary M. Zutter, John D. Pfeifer, Anna Belinda Berry · 2019 · Archives of Pathology & Laboratory Medicine
53. Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer
    Yoshie Kobayashi, Seung‐Oe Lim, Hirohito Yamaguchi · 2019 · Seminars in Cancer Biology
54. The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade
    Jean‐Philippe Foy, Chloé Bertolus, Marie‐Cécile Michallet, Sophie Deneuve, Roberto Incitti, Nathalie Bendriss‐Vermare, Marie Alexandra Albaret, Sandra Ortiz‐Cuaran, Emilie Thomas, Amélie Colombe et al. · 2017 · Annals of Oncology
55. Tumor Immunity and Survival as a Function of Alternative Neopeptides in Human Cancer
    Andrew J. Rech, David Balli, Alejandro Max Antonio Mantero, Hemant Ishwaran, Katherine L. Nathanson, Ben Z. Stanger, Robert H. Vonderheide · 2018 · Cancer Immunology Research
56. PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy
    Verena Rolfes, Christian Idel, Ralph Pries, Kirstin Plötze‐Martin, Jens Karsten Habermann, Timo Gemoll, Sabine Bohnet, Eicke Latz, Julika Ribbat‐Idel, Bernardo S. Franklin et al. · 2018 · Oncotarget
57. Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis
    Chengqian Yin, Bo Zhu, Ting Zhang, Tongzheng Liu, Shuyang Chen, Yu Liu, Xin Li, Xiao Miao, Shanshan Li, Xia Mi et al. · 2019 · Cell
58. Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy
    Ilio Vitale, Antonella Sistigu, Gwenola Manic, Nils-Petter Rudqvist, Zlatko Trajanoski, Lorenzo Galluzzi · 2019 · Trends in Cell Biology
59. Zeb1 induces immune checkpoints to form an immunosuppressive envelope around invading cancer cells
    Yan Guo, Xiaoqin Lu, Yao Chen, Beatriz E. Rendon, Robert A. Mitchell, Míriam Cuatrecasas, Marlies Cortés, Antonio A. Postigo, Yongqing Liu, Douglas C. Dean · 2021 · Science Advances
60. Genome-scale screens identify factors regulating tumor cell responses to natural killer cells
    Michal Sheffer, Emily Lowry, Nicky A. Beelen, Minasri Borah, Suha Naffar-Abu Amara, Chris C. Mader, Jennifer A. Roth, Aviad Tsherniak, Samuel S. Freeman, Olga Dashevsky et al. · 2021 · Nature Genetics
61. Neoadjuvant treatment of colorectal cancer: comprehensive review
    Henry George Smith, Per Johan Nilsson, Benjamin D. Shogan, Deena Pravin Harji, Maria Antonietta Gambacorta, Ângela Romano, Andreas Brandl, Camilla Qvortrup · 2024 · BJS Open
62. Leveraging Transcriptional Dynamics to Improve BRAF Inhibitor Responses in Melanoma
    Inna Smalley, Eunjung Kim, Jiannong Li, Paige Spence, Clayton J. Wyatt, Zeynep Eroglu, Vernon K. Sondak, Jane L. Messina, Nalan Akgül Babacan, Silvya Stuchi Maria–Engler et al. · 2019 · EBioMedicine
63. Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment
    Amblessed E. Onuma, Hongji Zhang, Hai Huang, Terence Marques Williams, Anne M. Noonan, Allan Tsung · 2020 · Gene Expression
64. Emerging Role of PD-1 in the Central Nervous System and Brain Diseases
    Junli Zhao, Alexus Roberts, Zilong Wang, Justin T Savage, Ru‐Rong Ji · 2021 · Neuroscience Bulletin
65. Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2
    Na Luo, Luigi Formisano, Paula I. González Ericsson, Violeta M. Sanchez, Phillip T. Dean, Susan R. Opalenik, Melinda E. Sanders, Rebecca S. Cook, Carlos L. Arteaga, Douglas Buckner Johnson et al. · 2018 · OncoImmunology
66. KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development
    Da Meng, Richard D. Carvajal · 2019 · American Journal of Clinical Dermatology
67. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy
    Aparna R. Parikh, Yuting He, Ted S. Hong, Ryan Bruce Corcoran, Jeff W. Clark, David P. Ryan, Lee Zou, David Tsai Ting, Daniel V.T. Catenacci, Joseph Chao et al. · 2019 · The Oncologist
68. Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies
    Robert John Walsh, Ross Andrew Soo · 2020 · Therapeutic Advances in Medical Oncology
69. Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response
    Yosuke Sato, Yu Fu, Hong Liu, Min Young Lee, Michael H. Shaw · 2021 · BMC Cancer
70. Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoediting
    Antonella Sistigu, Francesca Di Modugno, Gwenola Manic, Paola Nisticò · 2017 · Cytokine & Growth Factor Reviews
71. The perfect personalized cancer therapy: cancer vaccines against neoantigens
    Luigi Aurisicchio, Matteo Pallocca, Gennaro Ciliberto, Fabio Palombo · 2018 · Journal of Experimental & Clinical Cancer Research
72. Addressing intra-tumoral heterogeneity and therapy resistance
    Brad Rybinski, Kyuson Yun · 2016 · Oncotarget
73. Gene-expression profiling to predict responsiveness to immunotherapy
    Nigel Balfour Jamieson, Ajay V. Maker · 2016 · Cancer Gene Therapy
74. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
    Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups, Davide Bedognetti, Michele Ceccarelli, Lorenzo Galluzzi, Rongze Olivia. Lu, Karolina Palucka, Josue A. Samayoa, Stefani Spranger, Sarah E. Warren, Kwok‐Kin Wong et al. · 2019 · Journal for ImmunoTherapy of Cancer
75. TP53 Mutations Promote Immunogenic Activity in Breast Cancer
    Zhixian Liu, Zehang Jiang, Yingsheng Gao, Lirui Wang, Cai Chen, Xiaosheng Wang · 2018 · Journal of Oncology
76. Preoperative Radiomic Approach to Evaluate Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma Patients Using Contrast-Enhanced Computed Tomography
    Haotian Liao, Zhen Zhang, Jie Chen, Mingheng Liao, Lin Xu, Zhenru Wu, Kefei Yuan, Bin Song, Yong Zeng · 2019 · Annals of Surgical Oncology
77. Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival
    Mary Ann Wood, Benjamin R. Weeder, Julianne K. David, Abhinav Nellore, Reid F. Thompson · 2020 · Genome Medicine
78. PD-1 blockade-unresponsive human tumor-infiltrating CD8+ T cells are marked by loss of CD28 expression and rescued by IL-15
    Kyung Hwan Kim, Hong Kwan Kim, Hyung‐Don Kim, Chang Gon Kim, Hoyoung Lee, Ji Won Han, Seong Jin Choi, Seongju Jeong, Minwoo Jeon, Hyunglae Kim et al. · 2020 · Cellular and Molecular Immunology
79. Base editing screens map mutations affecting interferon-γ signaling in cancer
    Matthew A. Coelho, Sarah Cooper, Magdalena E Strauß, Emre Karakoç, Shriram G. Bhosle, Emanuel Gonçalves, Gabriele Picco, Thomas Burgold, Chiara Maria Cattaneo, Vivien Veninga et al. · 2023 · Cancer Cell
80. Exome-wide somatic mutation characterization of small bowel adenocarcinoma
    Ulrika A. Hänninen, Riku Katainen, Tomas J. Tanskanen, Roosa‐Maria Plaketti, Riku Laine, Jiri Hamberg, Ari P. Ristimaki, ­Eero Pukkala, Minna Taipale, Jukka‐Pekka Mecklin et al. · 2018 · PLoS Genetics
81. Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors
    Sanna Iivanainen, Jarkko Ahvonen, Aija Knuuttila, Satu Tiainen, Jussi Pekka Koivunen · 2019 · ESMO Open
82. Association ofMUC16Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors
    Lei Zhang, Xiaohong Han, Yuankai Shi · 2020 · JAMA Network Open
83. A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients
    Chuan Li, Yee Peng Phoon, Keaton S. Karlinsey, Ye F. Tian, Samjhana Thapaliya, Angkana Thongkum, Lili Qu, Alyssa Matz, Mark J. Cameron, Cheryl Cameron et al. · 2021 · The Journal of Experimental Medicine
84. Pyroptosis-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with UCEC
    Jinhui Liu, Rui Geng, Senmiao Ni, Lixin Cai, Sheng Yang, Fang Shao, Jianling Bai · 2022 · Molecular Therapy — Nucleic Acids
85. Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition
    Agnete S. T. Engelsen, Maria Lie Lotsberg, Raefa Abou Khouzam, Jean Paul Thiery, James B. Lorens, Salem Chouaı̈b, Stéphane Terry · 2022 · Frontiers in Immunology
86. VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma
    Xinqi Wu, Anita Giobbie‐Hurder, Xiaoyun Liao, Donald P. Lawrence, David F. McDermott, Jun Min Zhou, Scott J. Rodig, Frank Stephen Hodi · 2016 · Cancer Immunology Research
87. Expression of the Circadian Clock Gene BMAL1 Positively Correlates With Antitumor Immunity and Patient Survival in Metastatic Melanoma
    Leonardo Vinícius Monteiro de Assis, Gabriela Sarti Kinker, Maria Nathália Moraes, Regina Pekelmann Markus, Pedro Augusto Carlos Magno Fernandes, Ana Maria de Lauro Castrucci · 2018 · Frontiers in Oncology
88. Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity
    Lucas A. Horn, Jeffrey Riskin, Heidi Hempel, Kristen Fousek, Hanne Lind, Duane H. Hamilton, Kristen K. McCampbell, Dean Y. Maeda, John A. Zebala, Zhen Su et al. · 2020 · Journal for ImmunoTherapy of Cancer
89. The Resistance Mechanisms of Lung Cancer Immunotherapy
    Fen Wang, Shubin Wang, Qing Hua Zhou · 2020 · Frontiers in Oncology
90. Pharmacological Wnt Ligand Inhibition Overcomes Key Tumor-Mediated Resistance Pathways to Anti-PD-1 Immunotherapy
    Nicholas C. DeVito, Michael S. Sturdivant, Bala Thievanthiran, Christine Xiao, Michael P. Plebanek, April K.S. Salama, Georgia Marie Beasley, Alisha Holtzhausen, Veronica Novotny‐Diermayr, John H. Strickler et al. · 2020 · Cell Reports
91. Cancer Immunotherapies: From Efficacy to Resistance Mechanisms – Not Only Checkpoint Matters
    Shuyue Wang, Kun Xie, Tengfei Liu · 2021 · Frontiers in Immunology
92. Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy
    Camelia Y. J. Quek, Aditya Pratapa, Xinyu Bai, Ghamdan Al‐Eryani, Inês Pires da Silva, Aaron T. Mayer, Nenad Bartoniček, Kate Harvey, Nigel Gordon Maher, Jordan W. Conway et al. · 2024 · Cell Reports
93. Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma
    Ileabett M. Echevarría-Vargas, Patricia I. Reyes-Uribe, Adam N. Guterres, Xiangfan Yin, Andrew V. Kossenkov, Qin Liu, Gao Zhang, Clemens Krepler, Chaoran Cheng, Zhi Wei et al. · 2018 · EMBO Molecular Medicine
94. IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma
    Ting Li, Chao Zhang, Gang Zhao, Xinwei Zhang, Mengze Hao, Shafat Hassan, Min Zhang, Hong Zheng, Da Yang, Liang Liu et al. · 2020 · Cancer Letters
95. CD47: the next checkpoint target for cancer immunotherapy
    Ridong Feng, Zhao Hai, Jianguo Xu, Chongyang Shen · 2020 · Critical Reviews in Oncology/Hematology
96. Bacterial-Driven Inflammation and Mutant BRAF Expression Combine to Promote Murine Colon Tumorigenesis That Is Sensitive to Immune Checkpoint Therapy
    Christina E. DeStefano Shields, James Robert White, Liam Chung, Alyssa N. Wenzel, Jessica L Hicks, Ada J Tam, June L. Chan, Christine M. Dejea, Hongni Fan, John H. Michel et al. · 2021 · Cancer Discovery
97. Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment
    Carlota Rubio-Pérez, Ester Planas‐Rigol, Juan L. Trincado, Ester Bonfill‐Teixidor, Alexandra Arias, Doménica Marchese, Cátia Moutinho, Garazi Serna, Leire Pedrosa, Raffaella Iurlaro et al. · 2021 · Nature Communications
98. Systematic dissection of tumor-normal single-cell ecosystems across a thousand tumors of 30 cancer types
    Junho Kang, Jun Hyeong Lee, Hongui Cha, Jinhyeon An, Joonha Kwon, SeongWoo Lee, Seongryong Kim, Mert Yakup Baykan, So Yeon Kim, Dohyeon An et al. · 2024 · Nature Communications
99. Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
    Elisa Peranzoni, Vincenzo Ingangi, Elena Masetto, Laura Pinton, Ilaria Marigo · 2020 · Frontiers in Immunology
100. Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review
     Lokeswari Prathyusha Tangella, Michael E. Clark, Elin Solomonovna Gray · 2020 · Biochimica et Biophysica Acta (BBA) - General Subjects